Healthcare / Medical DevicesNYSE
$87.78
+2.18 (+2.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.4B · quality 83.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$152.9B
P/E
24.6x
↑EV/EBITDA
13.2x
↑ROE
12.5%
↑Gross Margin
56.4%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+3.0%
FCF CAGR
—
FCF margin
16.7%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.33B · net income $6.52B · FCF $7.39B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $44.33B | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B | $30.58B | $27.39B | $20.85B | $20.41B | $20.25B | $19.66B | $19.05B | $21.41B | $35.17B | $30.76B | $29.53B | $25.91B |
| Net Income | $6.52B | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B | $477.0M | $1.40B | $4.42B | $2.28B | $2.58B | $5.96B | $4.73B | $4.63B | $5.75B | $4.88B | $3.61B |
| EBITDA | $12.07B | $12.07B | $10.79B | $10.54B | $12.13B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 3.72 | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 | 2.92 | 1.49 | 1.62 | 3.72 | 3.01 | 2.96 | 1.77 | 1.50 | 1.11 |
| Gross Margin | 56.4% | 56.4% | 55.4% | 55.2% | 56.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 18.2% | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% | 15.5% | 14.2% | 11.9% | 5.7% | 14.5% | 14.1% | 12.8% | 10.9% | 7.1% | 7.6% | 17.3% | 20.3% | 19.3% | 17.7% |
| Net Margin | 14.7% | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% | 21.7% | 11.3% | 13.1% | 31.3% | 22.1% | 13.2% | 18.7% | 16.5% | 13.9% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.27 | 0.27 | 0.32 | 0.40 | 0.48 | 0.48 | 0.57 | 0.54 | 0.63 | 0.88 | 1.01 | 0.28 | 0.16 | 0.13 | 0.68 | 0.49 | 0.55 | 0.49 | 0.50 | 0.53 |
| Current Ratio | 1.39 | 1.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $7.39B | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B | $5.72B | $4.50B | $4.91B | $4.43B | $2.08B | $1.86B | $2.60B | $2.18B | $7.52B | $7.48B | — | — | — | — |
| Returns | ||||||||||||||||||||
| ROE | 12.5% | 12.5% | 28.1% | 14.8% | 18.9% | 19.8% | 13.7% | 11.9% | 7.8% | 1.5% | 6.8% | 20.9% | 10.6% | 10.2% | 22.3% | 19.3% | 20.4% | 24.8% | 27.9% | 20.3% |
| Valuation | ||||||||||||||||||||
| P/E | 24.59 | 24.59 | 14.90 | 33.99 | 28.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 13.16 | 13.16 | 19.13 | 19.21 | 16.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.95 | 2.95 | 4.17 | 5.02 | 5.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 5.7% | 5.7% | 4.6% | -8.1% | — | 24.5% | 8.5% | 4.3% | 11.6% | 31.3% | 2.2% | 0.8% | 3.0% | 3.2% | -11.0% | -39.1% | 14.3% | 4.2% | 13.9% | — |
| EPS Growth | -51.3% | -51.3% | 134.4% | -16.6% | — | 57.6% | 21.4% | 54.9% | 392.6% | -71.3% | -67.8% | 96.0% | -8.0% | -56.5% | 23.6% | 1.7% | 67.2% | 18.3% | 35.1% | — |
| Dividend Yield | 2.9% | 2.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
27.9%
EPS terminal req.
$7.79
Spread vs growth
-79.2%
5Y implied EPS CAGR
20.4%
EPS terminal req.
$9.42
Spread vs growth
-71.7%
10Y implied EPS CAGR
15.1%
EPS terminal req.
$15.18
Spread vs growth
-66.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.4%
Start / end P/E
17.5x → 23.6x
EPS bridge
7.64 → 3.72
Residual
-17.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.